Abstract

The present invention relates to the use of albumin for use in regulating immune cells in a subject in need thereof. The present invention relates particularly to a composition comprising human albumin for use in regulating immune cells in a subject having systemic inflammatory response syndrome.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to the field of liver diseases and, more in particular, to methods for determining the presence of acute-on chronic liver-failure or methods for determining the risk of a patient suffering from cirrhosis or delayed pre-ACLF of developing ACLF. The invention also relates to methods for distinguishing patients suffering from compensated cirrhosis, acutely decompensated cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, methods for determining the degree of systemic inflammation and methods for determining the presence of a bacterial infection with sepsis.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A lyophilized composition including polyclonal immunoglobulin M (IgM), including the steps of: a) providing an initial aqueous solution including IgM at a concentration between about 10 mg/mL and about 50 mg/mL, the polyclonal IgM being at least about 90% by weight of the total protein content of the composition; b) adding amino acids selected from the group consisting of proline, glycine, alanine, valine and hydroxyproline or a mixture thereof at a final concentration of about 0.15 M to about 0.45 M; polysorbate 80 (PS80) at a concentration between about 50 and about 200 ppm; and succinic acid at a concentration between about 1 mM and about 20 mM; and c) lyophilizing the IgM composition obtained in step b); wherein the lyophilized composition has a content of pentameric IgM higher than about 90% of the total IgM content, a content of IgM aggregates of less than about 1.5%.

IPC Classes  ?

• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A lyophilized composition including polyclonal immunoglobulin M (IgM), including the steps of: a) providing an initial aqueous solution including IgM at a concentration between about 10 mg/mL and about 50 mg/mL, the polyclonal IgM being at least about 90% by weight of the total protein content of the composition; b) adding amino acids selected from the group consisting of proline, glycine, alanine, valine and hydroxyproline or a mixture thereof at a final concentration of about 0.15 M to about 0.45 M; polysorbate 80 (PS80) at a concentration between about 50 and about 200 ppm; and succinic acid at a concentration between about 1 mM and about 20 mM; and c) lyophilizing the IgM composition obtained in step b); wherein the lyophilized composition has a content of pentameric IgM higher than about 90% of the total IgM content, a content of IgM aggregates of less than about 1.5%.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum

Abstract

The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 39/04 - Chelating agents

Abstract

Methods and compositions for treating and/or preventing disease are described. The compositions used in the methods include fractions and subfractions of blood plasma derived from donors, with efficacy in treating and/or preventing diseases both of the central nervous system and peripheral organs and tissues. Methods of manufacturing the compositions are also described.

IPC Classes  ?

• A61K 35/16 - Blood plasmaBlood serum
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention refers to a new method for producing a lyophilized pharmaceutical composition comprising human plasma-derived Factor Vlll/Von Willebrand Factor (FVIII/VWF) complex, comprising the steps of: a) providing an initial aqueous solution comprising FVIII/VWF with at least (90) III of FVIII per mg of total proteins, with a ratio of VWF/FVIII activity of at least 0.7; b) adding arginine, histidine, and human serum albumin (HAS); c) lyophilizing the FVIII/VWF solution obtained in step b); and d) reconstituting the lyophilized FVIII/VWF in water for injection thereby obtaining a therapeutic product adequate for the treatment of Hemophilia A and Von Willebrand Disease, wherein prior to administration to a patient, arginine is at a concentration between (42) and (98) mmol/L, histidine is at a concentration between (10) and (24) mmol/L, and albumin is at a concentration between (1) and (2.5) % (w/v), FVIII potency and VWF potency are equal to or higher than 200 ILI/mL, and the obtained product has a FVIII dose up to 3600 IU/vial and a VWF dose up to 5040 lll/vial.

IPC Classes  ?

• A61K 38/37 - Factors VIII
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Goods & Services

(1) Pharmaceutical preparations, namely, immunoglobulin for the treatment of immune deficiencies and autoimmune diseases

Abstract

Methods of preparation of therapeutic blood products from pooled plasma donors are described. The therapeutic blood products include, for example, blood plasma, blood plasma proteins, and blood plasma fractions with improved safety through the reduction in concentration or elimination of donor autoantibodies to FcεRIβ.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A machine for the preparation of pharmaceutical products in a sterile environment, including at least two stations of a line for preparing pharmaceutical products and automatic transport means for containers of pharmaceutical products, wherein the machine includes a robot positioned inside the machine and robot control means, the robot being a robotic arm which includes movement means for accessing the stations of the machine.

IPC Classes  ?

• B25J 21/00 - Chambers provided with manipulation devices
• A61J 1/16 - Holders for containers
• B25J 5/02 - Manipulators mounted on wheels or on carriages travelling along a guideway
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
• B65B 43/46 - Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up stateFeeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging positionLocating containers or receptacles at the filling positionSupporting containers or receptacles during the filling operation using grippers
• B65B 55/02 - Sterilising, e.g. of complete packages

Abstract

Methods and compositions for the treatment of wounds and ulcers in patients, in particular those patients suffering from chronic, non-healing wounds and ulcers. Fibrinogenases, such as plasmin show utility in decreasing plasma and or blood viscosity resulting in improved wound and ulcer healing in patients. The fibrinogenase may be one selected from the group consisting of an α-fibrinogenase, a β-fibrinogenase, a γ-fibrinogenase, a metallo-α-fibrinogenase, allium-α-fibrinogenase, a plasmin, and combination thereof.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

A method for obtaining Alpha-1 Proteinase Inhibitor for obtaining highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) includes preparing a solution of A1PI by concentrating an initial solution of A1PI by tangential flow filtration (TFF) against water. The final concentration of A1PI in the concentrated solution is at least 110 mg/ml. The TFF can be carried out against water for injection (WFD).

IPC Classes  ?

• C07K 14/81 - Protease inhibitors

Abstract

A composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) is for the treatment of a cognitive impairment by conventional therapeutic plasma exchange (TPE) and low-volume plasma exchange (LVPE) in a patient in need thereof. The patient has a Mini Mental State Examination (MMSE) greater or equal to 15.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 35/16 - Blood plasmaBlood serum
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A liquid composition comprising Factor VIII or Factor VIII/von Willebrand Factor complex comprising one or more stabilizers selected from glycerol, sorbitol, sucrose, trehalose, betaine, proline, arginine, histidine, NaCl, calcium, surfactants, antithrombin III, heparin, and albumin, wherein the content of proteases is 30 ng/1,000 FVIII IU or less, wherein osmolality of said composition is between 350 and 800 mOsmol/kg.

IPC Classes  ?

• A61K 38/37 - Factors VIII
• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes

Abstract

Use of albumin for the treatment of defective B-cell function Use of albumin for the treatment of defective B-cell function The present invention refers to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell Receptor density in a B-cell population.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Alpha-1-antitrypsin can be used as a therapeutic agent in patients that have suffered neural cell injury arising from traumatic or non-traumatic causes such as an ischemic stroke, cerebral hypoxia or spinal cord injuries. Alpha-1-antitrypsin can also be used in the treatment of neuropathic pain and the promotion of spinal cord revascularization following injury. Compositions including alpha-1 antitrypsin can be administered parenterally or by inhalation to the patients as part of a dosing regimen.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A device is for cooling plasma for a center for collecting plasma by plasmapheresis. The device includes a casing with at least one cooling chamber in the its interior. The chamber includes housings for cooling containers. The device also includes a refrigeration system arranged to refrigerate the chamber, and a control system for the refrigeration system. The refrigeration system and the control system are configured to control the temperature inside the device so as to allow the containers to be cooled to at least −30° C. in 60 minutes or less. The device includes at least two separate chambers contained in the casing, with each of the chambers including housings for bottles of plasma. The refrigeration system is arranged to refrigerate both chambers independently and the control system is configured to control the refrigeration of both chambers separately.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• A61J 1/16 - Holders for containers

Abstract

A method of treating a mild and moderate Alzheimer's Disease (AD), including conducting a low-volume plasma exchange (LVPE) to a subject suffering from the mild and moderate Alzheimer's Disease (AD); and administering an effective amount of a composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) to the subject during the LVPE to replace with a subject's plasma. Use of low volume plasma exchange for the treatment of Alzheimer's Disease in early and middle stages. A composition including human albumin at a concentration between 5% (w/v) and 25% (w/v) for the treatment of mild and moderate Alzheimer's Disease (AD) by low-volume plasma exchange (LVPE).

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Chemical preparations for scientific purposes; chemical preparations for supplementation of fibrinogen not for medical or veterinary use; Biological agents for industrial and scientific purposes made from human blood, blood plasma or blood serum, namely, proteins and protein preparations in the nature of albumin, immune globulins and fibrinogen; Biological agents for industrial and scientific purposes, namely, blood-derived proteins in the nature of coagulation factors; Biological agents for commercial and industrial purposes, namely, blood-derived plasma and blood serum sample preparations Pharmaceutical, medical and veterinary preparations for the treatment congenital and acquired fibrinogen deficiency; blood substitutes and blood plasma substitutes for human use; blood serum and blood serum proteins made from human blood for medical use; coagulants made from human blood plasma for medical use; fibrinogen, fibrinogen made from human blood plasma for medical use; pharmaceutical preparations for use in treating blood diseases and for use in medical transplants and oncology; veterinary preparations for treating blood diseases; pharmaceutical preparations for use in blood coagulation

Goods & Services

Chemical preparations for scientific purposes; chemical preparations for supplementation of fibrinogen not for medical or veterinary use; Biological agents for industrial and scientific purposes made from human blood, blood plasma or blood serum, namely, proteins and protein reparations in the nature of albumin, immune globulins and fibrinogen; Biological agents for industrial and scientific purposes, namely, blood-derived proteins in the nature of coagulation factors; Biological agents for commercial and industrial purposes, namely, blood-derived plasma and blood serum sample preparations Pharmaceutical, medical and veterinary preparations for the treatment congenital and acquired fibrinogen deficiency; blood substitutes and blood plasma substitutes for human use; blood serum and blood serum proteins made from human blood for medical use; coagulants made from human blood plasma for medical use; fibrinogen, fibrinogen made from human blood plasma for medical use; pharmaceutical preparations for use in treating blood diseases and for use in medical transplants and oncology; veterinary preparations for treating blood diseases; pharmaceutical preparations for use in blood coagulation

Goods & Services

(1) Chemical products for commercial or scientific purposes; biological agents for commercial and scientific purposes, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; biological agents for commercial and scientific purposes, namely, coagulation factors; biological agents for commercial and scientific purposes, namely, plasma and serum preparations (2) Pharmaceutical products, medical and veterinary preparations; blood substitute, and blood plasma substitute; serum preparations, in particular, serum proteins and solutions containing the same; proteins and protein preparations made from human blood, blood plasma or blood serum; coagulation factors; fibrinogen, fibrinogen made from human blood plasma; pharmaceutical and veterinary products for hematology, intensive medicine, transplantation medicine, oncology, for influencing blood diseases, for influencing blood coagulation

Goods & Services

(1) Chemical products for commercial or scientific purposes; biological agents for commercial and scientific purposes, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; biological agents for commercial and scientific purposes, namely, coagulation factors; biological agents for commercial and scientific purposes, namely, plasma and serum preparations (2) Pharmaceutical products, medical and veterinary preparations; blood substitute, and blood plasma substitute; serum preparations, in particular, serum proteins and solutions containing the same; proteins and protein preparations made from human blood, blood plasma or blood serum; coagulation factors; fibrinogen, fibrinogen made from human blood plasma; pharmaceutical and veterinary products for hematology, intensive medicine, transplantation medicine, oncology, for influencing blood diseases, for influencing blood coagulation

Goods & Services

(1) Chemical products for commercial or scientific purposes; biological agents for commercial and scientific purposes, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; biological agents for commercial and scientific purposes, namely, coagulation factors; biological agents for commercial and scientific purposes, namely, plasma and serum preparations (2) Pharmaceutical products, medical and veterinary preparations; blood substitute, and blood plasma substitute; serum preparations, in particular, serum proteins and solutions containing the same; proteins and protein preparations made from human blood, blood plasma or blood serum; coagulation factors; fibrinogen, fibrinogen made from human blood plasma; pharmaceutical and veterinary products for hematology, intensive medicine, transplantation medicine, oncology, for influencing blood diseases, for influencing blood coagulation

Goods & Services

Pharmaceutical preparations; medical preparations.

Abstract

The present invention relates to the use of Antithrombin in the treatment of stroke.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• C07K 14/81 - Protease inhibitors
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed herein are methods and compositions for preserving or reconditioning organs prior to transplant. The compositions of the present invention contain plasmin and/or functionally active mutants thereof formulated in a pharmaceutically acceptable organ preservation solution. The compositions are stable and non-toxic to the organ intended for transplant.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) includes PEG precipitation of the IgM, resuspension of the precipitated IgM; (c) performing an adsorption chromatography, removing isoagglutinins A/B, nanofiltration, and ultrafiltration/diafiltration. The precipitation can be performed at a pH between 4.5 and 6.5, and the PEG can be at a concentration between 5 (w/v) and 11% (w/v).

IPC Classes  ?

• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A unit for automatically collecting blood and/or plasma, includes a number of stations for automatically collecting blood and/or plasma and at least one venepuncture robot. The robot has a blood vessel detector. The robot is fitted on a linear guide and is movable on the linear guide. The stations are laid out along the linear guide such that the robot can move along the linear guide to access the stations.

IPC Classes  ?

• A61B 5/15 - Devices for taking samples of blood
• A61B 34/30 - Surgical robots
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Goods & Services

Pharmaceutical and medical preparations, in particular, human immune globulin.

Goods & Services

Pharmaceutical and medical preparations, in particular, human immune globulin.

Abstract

Bone Composite and Compositions, particularly multicomponent or multipart compositions, are for the preparation of bone constructs for use in trauma, or cancer patients for example. The multipart compositions are based around combinations of fibrinogen, thrombin, hydrogels and calcium/phosphorous salts. The multipart compositions are capable of being printed to yield bone constructs using a 3D printing process to produce accurate and precise bone constructs of a desired geometry.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 10/00 - Processes of additive manufacturing
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material

Goods & Services

Medical testing for diagnostic or treatment purposes in the field of cirrhosis; medical services for the treatment of cirrhosis

Goods & Services

Medical testing for diagnostic or treatment purposes; medical services.

Abstract

Disclosed herein are human blood fractions depleted of disease-causing extracellular vesicles, prepared by plasma exchange, that may find use in the treatment of a condition selected from the group consisting of neurodegenerative disease, autoimmune disease, cardiovascular disease, renal disease, and liver disease. In particular, the depleted blood fractions may find use in treating neurodegenerative diseases such as Parkinson's Disease or Alzheimer's Disease.

IPC Classes  ?

• A61K 35/16 - Blood plasmaBlood serum
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are human blood fractions depleted of disease-causing extracellular vesicles, prepared by plasma exchange, that may find use in the treatment of a cancer. In particular, the depleted blood fractions may find use in treating KRAS mutant cancers.

IPC Classes  ?

• A61K 35/16 - Blood plasmaBlood serum
• A61P 35/00 - Antineoplastic agents

Goods & Services

Diagnostic kits comprised of medical diagnostic reagents and nucleic acids for testing blood for detection and analysis of Human Immunodeficiency Type 1 (HIV-1), Human Immunodeficiency Type 2 (HIV-2), Hepatitis C (HCV), Hepatitis B (HBV) and West Nile (WNV) viruses

Goods & Services

Pharmaceutical preparations; medical preparations.

Abstract

Compositions include highly concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

IPC Classes  ?

• A61K 38/55 - Protease inhibitors
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates

Abstract

A method is for the treatment of a viral infection with human alpha-1 antitrypsin (A1AT). Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient, include administering to the patient a therapeutically effective amount of human alpha-1 antitrypsin. The A1AT is administered in an amount between 60 mg/kg and 200 mg/kg. Methods and compositions for the treatment of Cytokine Release Syndrome (CRS) in a patient, include administering to the patient a therapeutically effective amount of an inhibitor of interleukin-6 in combination with a therapeutically effective amount of A1AT.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans

Goods & Services

(1) Pharmaceuticals preparations, namely enzyme inhibitor for pulmonary function

Abstract

Pharmaceutical compositions containing transferrin or lactoferrin for use in promoting or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event. The neurodegenerative event may be caused by a neurodegenerative disease such as Alzheimer's, Parkinson's, Huntington's, or amyotrophic lateral sclerosis. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

A system for dispensing a liquid in a closed chamber includes at least one rapid transfer port in at least one wall of the closed chamber. In addition, a liquid is dispensed in a closed chamber that includes at least one rapid transfer port in at least one wall of the closed chamber.

IPC Classes  ?

• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B25J 21/00 - Chambers provided with manipulation devices
• B01L 1/00 - EnclosuresChambers
• B01L 3/02 - BurettesPipettes

Abstract

Method for the treatment of virus infection with IVIG and convalescent plasma. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of intravenous Immunoglobulin G (IVIG) in an amount of about 0.5 g/kg to about 8 g/kg. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of convalescent anti-SARS-CoV-2 plasma, wherein the convalescent anti-SARS-CoV-2 plasma is treated with methylene blue for pathogen inactivation.

IPC Classes  ?

• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
• A61K 41/10 - Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
• A61K 35/16 - Blood plasmaBlood serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Hyperimmune IgG and/or IgM compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor. A liquid therapeutic hyperimmune globulin composition including human plasma-derived immunoglobulin G (IgG) having antibody titre between 250 and 2,500 per mg/mL of IgG and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titer) between 1.5 and 15 per mg/mL of IgG for use in the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof. A liquid therapeutic or prophylactic hyperimmune immunoglobulin composition including human plasma-derived immunoglobulin M (IgM) having a SARS-CoV-2 titre between 2,000 and 17,000 and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titre) between 200 and 70,000, methods for preparing thereof, and the use thereof for the treatment or prophylaxis of COVID-19. A method for obtaining hyperimmune human plasma from a donor for use in the treatment of COVID-19.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 35/16 - Blood plasmaBlood serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A system for the sterile filling of containers for pharmaceutical products, which includes a device for sterilizing containers and a machine for filling sterilized containers, wherein the device for sterilizing containers includes at least one autoclave, and wherein the system includes an automated container-accumulation device and means for automatically transporting the containers sterilized in the autoclave from said autoclave to the container-filling machine via said container-accumulation device.

IPC Classes  ?

• B65B 55/06 - Sterilising wrappers or receptacles prior to, or during, packaging by heat
• A61L 2/07 - Steam
• A61L 2/24 - Apparatus using programmed or automatic operation
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers

Abstract

A composition including albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of the composition equivalent to approximately 100% of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Collection of human blood, plasma and blood components; operation of human plasma donor centers

Goods & Services

Electronic downloadable publications, namely, brochures, informational flyers and teaching materials for use by medical professionals, patients and caregivers featuring information for the treatment of immuno deficiency disorders Information on financial administration of patient reimbursement programs; providing insurance information for patients diagnosed with immuno deficiency disorders regarding medication access and reimbursement programs and insurance premium and co-pay assistance Educational services, namely, providing training to patients with immune deficiency disorders for self-administration of medication and management of immunoglobulin therapy; providing a website featuring non-downloadable videos in the treatment of immuno deficiency disorders

Goods & Services

Pharmaceutical and medical preparations, in particular, human immune globulin.

Goods & Services

Pharmaceutical and medical preparations, in particular, human immune globulin.

Abstract

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

IPC Classes  ?

• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A01K 67/027 - New or modified breeds of vertebrates
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention refers to a new method for producing a lyophilized pharmaceutical composition comprising human plasma-derived Factor Vlll/Von Willebrand Factor (FVIII/VWF) complex, comprising the steps of: a) providing an initial aqueous solution comprising FVIII/VWF with at least (90) III of FVIII per mg of total proteins, with a ratio of VWF/FVIII activity of at least 0.7; b) adding arginine, histidine, and human serum albumin (HAS); c) lyophilizing the FVIII/VWF solution obtained in step b); and d) reconstituting the lyophilized FVIII/VWF in water for injection thereby obtaining a therapeutic product adequate for the treatment of Hemophilia A and Von Willebrand Disease, wherein prior to administration to a patient, arginine is at a concentration between (42) and (98) mmol/L, histidine is at a concentration between (10) and (24) mmol/L, and albumin is at a concentration between (1) and (2.5) % (w/v), FVIII potency and VWF potency are equal to or higher than 200 ILI/mL, and the obtained product has a FVIII dose up to 3600 lU/vial and a VWF dose up to 5040 lll/vial.

IPC Classes  ?

• A61K 38/37 - Factors VIII
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Abstract

The present invention refers to a new method for producing a lyophilized pharmaceutical composition comprising human plasma-derived Factor Vlll/Von Willebrand Factor (FVIII/VWF) complex, comprising the steps of: a) providing an initial aqueous solution comprising FVIII/VWF with at least (90) III of FVIII per mg of total proteins, with a ratio of VWF/FVIII activity of at least 0.7; b) adding arginine, histidine, and human serum albumin (HAS); c) lyophilizing the FVIII/VWF solution obtained in step b); and d) reconstituting the lyophilized FVIII/VWF in water for injection thereby obtaining a therapeutic product adequate for the treatment of Hemophilia A and Von Willebrand Disease, wherein prior to administration to a patient, arginine is at a concentration between (42) and (98) mmol/L, histidine is at a concentration between (10) and (24) mmol/L, and albumin is at a concentration between (1) and (2.5) % (w/v), FVIII potency and VWF potency are equal to or higher than 200 ILI/mL, and the obtained product has a FVIII dose up to 3600 lU/vial and a VWF dose up to 5040 lll/vial.

IPC Classes  ?

• A61K 38/37 - Factors VIII
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Goods & Services

Albuminous preparations for medical purposes.

Abstract

The present invention refers to a composition comprising human albumin at a concentration between 5 % (w/v) and 25 % (w/v) for the treatment of a cognitive impairment by conventional therapeutic plasma exchange (TPE) and low volume plasma exchange (LVPE) in a patient in need thereof, wherein said patient has a Mini Mental State Examination (MMSE) greater or equal to 15.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a composition comprising human albumin at a concentration of between 5 % (w/v) and 25 % (w/v) for the treatment of a cognitive impairment by therapeutic plasma exchange (TPE) and low-volume plasma exchange (LVPE) in a patient in need thereof, where said patient has a Mini Mental State Examination (MMSE) greater or equal to 15.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61K 38/38 - Albumins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

A liquid composition comprising Factor VIII or Factor VIII/von Willebrand Factor complex comprising one or more stabilizers selected from glycerol, sorbitol, sucrose, trehalose, betaine, proline, arginine, histidine, NaCl, calcium, surfactants, antithrombin III, heparin, and albumin, wherein the content of proteases is 30 ng/1,000 FVIII IU or less, wherein osmolality of said composition is between 350 and 800 mOsmol/kg.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A liquid composition comprising Factor VIII or Factor VIII/von Willebrand Factor complex comprising one or more stabilizers selected from glycerol, sorbitol, sucrose, trehalose, betaine, proline, arginine, histidine, NaCl, calcium, surfactants, antithrombin III, heparin, and albumin, wherein the content of proteases is 30 ng/1,000 FVIII IU or less, wherein osmolality of said composition is between 350 and 800 mOsmol/kg.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

An in vitro method for diagnosing Alzheimer's disease (AD) includes determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF), and comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Device (1) for cooling plasma for a centre for collecting plasma by plasmapheresis, said device comprising a casing comprising at least two separate chambers (5), each of the chambers comprising housings (42, 43) for bottles (9) of plasma; the device also comprising a refrigeration system and a control system, being configured to control the temperature inside the device so as to allow the bottles to be cooled to at least -30°C in 60 minutes or less; wherein the refrigeration system is arranged to refrigerate both chambers independently and the control system is configured to control the refrigeration of both chambers separately. Being able to produce two simultaneous cooling cycles is particularly advantageous in mobile distribution centres. Cooling of the bottles may be made by contact with the housings or by natural convection. A distribution centre comprising such a device, e.g. a mobile distribution centre in form of a motor bus, is also disclosed.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• F25D 11/02 - Self-contained movable devices associated with refrigerating machinery, e.g. domestic refrigerators with cooling compartments at different temperatures

Abstract

The present invention relates to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell receptor density in a B-cell population.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

A method for controlling the concentration of an anticoagulant composition added to a donor's plasma during a fixed volume apheresis extraction process involves utilizing a donor's hematocrit (HCT) measurement to determine a ratio of the anticoagulant composition to the donor's uncoagulated blood during the apheresis extraction process. The ratio of the anticoagulant composition to the donor's uncoagulated blood during the apheresis extraction process is additionally determined as a function of the total collection volume and/or the desired volume of the anticoagulant composition.

IPC Classes  ?

• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration

Abstract

The present invention relates to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell receptor density in a B-cell population.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to the use of alpha-1 antitrypsin as a therapeutic agent in patients who have suffered neural cell injury arising from traumatic or non- traumatic causes, such as an ischemic stroke, cerebral hypoxia or spinal cord injuries. Alpha-1 antitrypsin administered in accordance with the treatment regimen of the present invention may also prove useful in the treatment of neuropathic pain and the promotion of spinal cord revascularisation following injury thereto. Compositions comprising alpha-1 antitrypsin may be administered parenterally or by inhalation to the patients as part of an innovative dosing regimen.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present invention is related to the use of alpha-1-antitrypsin as a therapeutic agent in patients that have suffered neural cell injury arising from traumatic or non-traumatic causes such as an ischemic stroke, cerebral hypoxia or spinal cord injuries. Alpha-1-antitrypsin administered in accordance with the treatment regimen of the present invention may also find utility in the treatment of neuropathic pain and the promotion of spinal cord revascularisation following injury thereto. Compositions comprising alpha-1 antitrypsin may be administered parenterally or by inhalation to the patients as part of an innovative dosing regimen.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• C07K 14/81 - Protease inhibitors

Abstract

Machine (1) for the preparation of pharmaceutical products in a sterile environment, said machine (1) comprising at least two stations of a line (10) for preparing pharmaceutical products and automatic transport means for containers (5) of pharmaceutical products, wherein the machine (1) comprises a robot (2) positioned inside the machine (1) and means for controlling said robot, said robot (2) being a robotic arm which comprises movement means for accessing the stations of the machine (1).

IPC Classes  ?

• B25J 5/02 - Manipulators mounted on wheels or on carriages travelling along a guideway
• B25J 9/00 - Programme-controlled manipulators
• B25J 21/00 - Chambers provided with manipulation devices
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 55/02 - Sterilising, e.g. of complete packages
• B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
• B65B 57/04 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of binding or wrapping material, containers, or packages and operating to control, or to stop, the feed of such material, containers, or packages

Abstract

Machine (1) for the preparation of pharmaceutical products in a sterile environment, said machine (1) comprising at least two stations of a line (10) for preparing pharmaceutical products and automatic transport means for containers (5) of pharmaceutical products, wherein the machine (1) comprises a robot (2) positioned inside the machine (1) and means for controlling said robot, said robot (2) being a robotic arm which comprises movement means for accessing the stations of the machine (1).

IPC Classes  ?

• B25J 5/02 - Manipulators mounted on wheels or on carriages travelling along a guideway
• B25J 9/00 - Programme-controlled manipulators
• B25J 21/00 - Chambers provided with manipulation devices
• B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
• B65B 55/02 - Sterilising, e.g. of complete packages
• B65B 57/04 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of binding or wrapping material, containers, or packages and operating to control, or to stop, the feed of such material, containers, or packages

Abstract

The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 31/295 - Iron group metal compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61P 39/04 - Chelating agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are methods and compositions for the treatment of wounds and ulcers in patients, in particular those patients suffering from chronic, non-healing wounds and ulcers. Fibrinogenases, such as plasmin show utility in decreasing plasma and or blood viscosity resulting in improved wound and ulcer healing in patients.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed herein are methods and compositions for the treatment of wounds and ulcers in patients, in particular those patients suffering from chronic, non-healing wounds and ulcers. Fibrinogenases, such as plasmin show utility in decreasing plasma and or blood viscosity resulting in improved wound and ulcer healing in patients.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Unit for automatically collecting blood and/or plasma, comprising a plurality of stations for automatically collecting blood and/or plasma and at least one venipuncture robot. The robot comprises means for detecting blood vessels. Said robot is mounted on a linear guide and is movable on said linear guide. The stations are distributed along the linear guide such that the robot can move along the linear guide to access said stations.

IPC Classes  ?

• A61B 5/153 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes
• A61B 34/30 - Surgical robots
• A61B 5/15 - Devices for taking samples of blood

Goods & Services

Collection of human blood, plasma and blood components; operation of human blood plasma donor centers

Goods & Services

Collection of human blood, plasma and blood components; operation of human blood plasma donor centers

Abstract

A composition is for improving the culture and implantation of mammalian embryos. The composition includes one or more of the fractions of human plasma fractionation using the Cohn method wherein in the composition human serum albumin (HSA) is between 90% and 96% of the total proteins in the composition, alfa and beta globulins are between 3.5% and 9.99% of the total proteins in the composition, and gamma globulin is between 0.01% and 0.5% of the total proteins in the composition.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

Disclosed herein are pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/22 - Hormones
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) including the steps of (a) PEG precipitation of the IgM; (b) resuspension of the precipitated IgM; (c) performing an adsorption chromatography; (d) removing isoagglutinins A/B; (e) nanofiltration; and (f) ultrafiltration/diafiltration. In the method for preparing the composition, the precipitation step a) is preferably performed at a pH between 4.5 and 6.5, and the PEG is preferably at a concentration between 5 (w/v) and 11% (w/v).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum

Abstract

Disclosed herein are pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/22 - Hormones
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are pharmaceutical compositions containing transferrin or lactoferrin for use in promoting or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event. The neurodegenerative event may be caused by a neurodegenerative disease such as Alzheimer's, Parkinson's, Huntington's, or amyotrophic lateral sclerosis. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/22 - Hormones
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for preparing a composition of human plasma-derived immunoglobulin M (IgM) including the steps of (a) PEG precipitation of the IgM; (b) resuspension of the precipitated IgM; (c) performing an adsorption chromatography; (d) removing isoagglutinins A/B; (e) nanofiltration; and (f) ultrafiltration/diafiltration. In the method for preparing the composition, the precipitation step a) is preferably performed at a pH between 4.5 and 6.5, and the PEG is preferably at a concentration between 5 (w/v) and 11% (w/v).

IPC Classes  ?

• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Disclosed herein are pharmaceutical compositions containing transferrin or lactoferrin for use in promoting or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event. The neurodegenerative event may be caused by a neurodegenerative disease such as Alzheimer's, Parkinson's, Huntington's, or amyotrophic lateral sclerosis. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Compositions include highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly-concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

IPC Classes  ?

• A61K 38/55 - Protease inhibitors
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates

Abstract

The present disclosure refers to a liquid therapeutic hyperimmune globulin composition comprising human plasma-derived immunoglobulin G (IgG) having antibody titre between 250 and 2,500 per mg/mL of IgG and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titer) between 1.5 and 15 per mg/mL of IgG for use in the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof. It also refers to a liquid therapeutic or prophylactic hyperimmune immunoglobulin composition comprising human plasma-derived immunoglobulin M (IgM) having a SARS-CoV-2 titre between 2,000 and 17,000 and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titre) between 200 and 70,000, methods for preparing thereof, and the use thereof for the treatment or prophylaxis of COVID-19. Finally, it also refers to a method for obtaining hyperimmune human plasma from a donor for use in the treatment of COVID-19.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present disclosure refers to a liquid therapeutic hyperimmune globulin composition comprising human plasma-derived immunoglobulin G (IgG) having antibody titre between 250 and 2,500 per mg/mL of IgG and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titer) between 1.5 and 15 per mg/mL of IgG for use in the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof. It also refers to a liquid therapeutic or prophylactic hyperimmune immunoglobulin composition comprising human plasma-derived immunoglobulin M (IgM) having a SARS-CoV-2 titre between 2,000 and 17,000 and/or a SARS-CoV-2 neutralization activity (IC50 neutralization titre) between 200 and 70,000, methods for preparing thereof, and the use thereof for the treatment or prophylaxis of COVID-19. Finally, it also refers to a method for obtaining hyperimmune human plasma from a donor for use in the treatment of COVID-19.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

Method for the treatment of a viral infection with human alpha-1 antitrypsin The present invention relates to method and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of human alpha-1 antitrypsin, wherein A1AT is administered in an amount between 60 mg/kg and 200 mg/kg. The present invention also refers to methods and compositions for the treatment of Cytokine Release Syndrome (CRS) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an inhibitor of interleukin-6 in combination with a therapeutically effective amount of A1AT.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 38/20 - Interleukins
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure refers to methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of intravenous Immunoglobulin G (IVIG) in an amount of about 0.5 g/kg to about 8 g/kg. The present disclosure also refers to methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of convalescent anti-SARS-CoV-2 plasma, wherein the convalescent anti-SARS-CoV-2 plasma is treated with methylene blue for pathogen inactivation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Goods & Services

Laboratory analyzers for medical use for measuring, testing and analyzing blood and other bodily fluids during in vitro diagnostic tests

Abstract

The invention relates to a system for the sterile filling of containers for pharmaceutical products, which comprises a device for sterilising containers and a machine for filling sterilised containers, wherein the device for sterilising containers comprises at least one autoclave, and wherein the system comprises an automated container-accumulation device and means for automatically transporting the containers sterilised in the autoclave from said autoclave to the container-filling machine via said container-accumulation device.

IPC Classes  ?

• A61L 2/07 - Steam
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor

Abstract

The invention relates to a system for the sterile filling of containers for pharmaceutical products, which comprises a device for sterilising containers and a machine for filling sterilised containers, wherein the device for sterilising containers comprises at least one autoclave, and wherein the system comprises an automated container-accumulation device and means for automatically transporting the containers sterilised in the autoclave from said autoclave to the container-filling machine via said container-accumulation device.

IPC Classes  ?

• A61L 2/07 - Steam

Abstract

The present invention relates to a composition comprising albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a composition comprising albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention discloses a system for dispensing a liquid into a closed enclosure comprising at least one rapid transfer port in at least one wall of said enclosure. Additionally, the present invention also discloses a method for dispensing a liquid into an enclosure comprising at least one rapid transfer port in at least one wall of said enclosure.

IPC Classes  ?

• B25J 21/00 - Chambers provided with manipulation devices
• B01L 1/04 - Dust-free rooms or enclosures
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B67C 3/22 - Bottling liquids or semiliquidsFilling jars or cans with liquids or semiliquids using bottling or like apparatus Details
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to a system for dispensing a liquid in a closed chamber which comprises at least one rapid transfer port in at least one wall of said closed chamber. In addition, the present invention also relates to a method of dispensing a liquid in a closed chamber which comprises at least one rapid transfer port in at least one wall of said closed chamber.

IPC Classes  ?

• B01L 1/04 - Dust-free rooms or enclosures
• B25J 21/00 - Chambers provided with manipulation devices
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B67C 3/22 - Bottling liquids or semiliquidsFilling jars or cans with liquids or semiliquids using bottling or like apparatus Details

Abstract

Methods for obtaining highly-concentrated Alpha- 1 Proteinase Inhibitor (A1 PI) comprising a step of preparing a solution of A1 PI by concentrating an initial solution of A1 PI by tangential flow filtration (TFF) against water wherein the final concentration of A1 PI in the concentrated solution is at least 110 mg/ml.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• B01D 61/14 - UltrafiltrationMicrofiltration
• C07K 14/81 - Protease inhibitors

Abstract

Methods for obtaining highly-concentrated Alpha- 1 Proteinase Inhibitor (A1 PI) comprising a step of preparing a solution of A1 PI by concentrating an initial solution of A1 PI by tangential flow filtration (TFF) against water wherein the final concentration of A1 PI in the concentrated solution is at least 110 mg/ml.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• B01D 61/14 - UltrafiltrationMicrofiltration

Goods & Services

Pharmaceutical preparations, namely, proteolytic enzyme inhibitor

Abstract

Disclosed herein are multicomponent or multipart compositions for the preparation of bone constructs for use of trauma, or cancer patients for example. The multipart compositions are based around innovative combinations of fibrinogen, thrombin, hydrogels and calcium/phosphorous salts. Advantageously, the multipart compositions are capable of being printed to yield bone constructs using a 3D printing process to produce accurate and precise bone constructs of a desired geometry.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

Disclosed herein are multicomponent or multipart compositions for the preparation of bone constructs for use of trauma, or cancer patients for example. The multipart compositions are based around innovative combinations of fibrinogen, thrombin, hydrogels and calcium/phosphorous salts. Advantageously, the multipart compositions are capable of being printed to yield bone constructs using a 3D printing process to produce accurate and precise bone constructs of a desired geometry.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing